Molecular Dysregulation in Fuchs Corneal Endothelial Dystrophy

福克斯角膜内皮营养不良的分子失调

• 批准号: 10738881
• 负责人: Rajalekshmy Shyam
• 金额: $ 24.9万
• 依托单位: TRUSTEES OF INDIANA UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10738881
• 关键词: Affect; Age; Alternative Therapies; Animal Model; Bilateral; Cell Line; Cells; Characteristics; Corneal Endothelium; Corneal edema; Data; Development; Diabetes Mellitus; Disease; Disease Progression; Drug Targeting; Endothelial Cells; Endothelium; Failure; Fuchs' Endothelial Dystrophy; Functional disorder; Genes; Graft Rejection; Infection; Integrin Signaling Pathway; Integrins; Keratoplasty; Knockout Mice; Malignant Neoplasms; Mesenchymal; Molecular; Mus; Mutate; Mutation; Oxidative Stress; Pathogenesis; Pathway interactions; Patients; Persons; Pharmacologic Substance; Phenocopy; Phenotype; Physiologic Intraocular Pressure; Repression; Role; Signal Pathway; Signal Transduction; Testing; Therapeutic; Tissue Donors; United States; WNT Signaling Pathway; aging population; common treatment; experimental study; mouse model; standard care

Fuchs Endothelial Corneal Dystrophy (FECD) is a blinding disease that affects 4% over the age of 40 in the United States. There is no cure for this condition. Corneal tranplantation is the prevalent treatment. With the aging population, there is increasing scarcity of donor tissues. In addition, tranplant failures due to graft rejections occur in 10-25% of corneal transplantations. This proposal focuses on identifying previously understudied molecular signaling pathways in FECD. Successful completion of the specific aims in this proposal can lead to alternative therapies for FECD.

福克斯内皮性角膜营养不良 (FECD) 是一种致盲性疾病，影响 4% 的 40 岁以上人群 美国。这种情况无法治愈。角膜移植是普遍的治疗方法。 随着人口老龄化，供体组织日益短缺。此外，由于移植失败 10-25% 的角膜移植发生移植排斥反应。该提案的重点是确定 之前对 FECD 中的分子信号传导途径进行了充分研究。顺利完成具体任务 该提案的目标可以为 FECD 带来替代疗法。